Immuneering (IMRX) Equity Average: 2021-2024
Historic Equity Average for Immuneering (IMRX) over the last 3 years, with Sep 2024 value amounting to $62.0 million.
- Immuneering's Equity Average fell 43.40% to $62.0 million in Q3 2024 from the same period last year, while for Sep 2024 it was $62.0 million, marking a year-over-year decrease of 43.40%. This contributed to the annual value of $100.2 million for FY2023, which is 24.60% down from last year.
- Latest data reveals that Immuneering reported Equity Average of $62.0 million as of Q3 2024, which was down 14.48% from $72.5 million recorded in Q2 2024.
- In the past 5 years, Immuneering's Equity Average ranged from a high of $157.1 million in Q4 2021 and a low of $61.6 million during Q3 2021.
- Over the past 3 years, Immuneering's median Equity Average value was $106.4 million (recorded in 2023), while the average stood at $106.3 million.
- Its Equity Average has fluctuated over the past 5 years, first spiked by 107.53% in 2022, then tumbled by 43.40% in 2024.
- Quarterly analysis of 4 years shows Immuneering's Equity Average stood at $157.1 million in 2021, then dropped by 26.26% to $115.9 million in 2022, then fell by 16.03% to $97.3 million in 2023, then plummeted by 43.40% to $62.0 million in 2024.
- Its last three reported values are $62.0 million in Q3 2024, $72.5 million for Q2 2024, and $84.6 million during Q1 2024.